Kommentar zu S. Denzinger et al., S. 58

Literatur

• 1 Anderstrom C, Johansson S, Nilsson S. The significance of lamina propria invasion on the prognosis of patients with bladder tumors.  J Urol. 1980;  124 (1) 23-26
• 2 Herr H W, Laudone V P, Badalament R A. et al . Bacillus Calmette-Guerin therapy alters the progression of superficial bladder cancer.  J Clin Oncol. 1988;  6 (9) 1450-1455
• 3 Herr H W. Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome.  Br J Urol. 1997;  80 (5) 762-765
• 4 Herr H W, Sogani P C. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?.  J Urol. 2001;  166 (4) 1296-1299
• 5 Kiemeney l A, Witjes J A, Heijbroek R P, Verbeek A L, Debruyne F M. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer.  J Urol. 1993;  150 (1) 60-64
• 6 Klän R, Hardung R, Meir T, Miller K. Progression in T1G3 urothelial bladder cancer: Impact of therapy.  J Urol. 1995;  153 (suppl) 22
• 7 Lamm D L, Blumenstein B A, Crawford E D. et al . A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder.  N Engl J Med. 1991;  325 (17) 1205-1209
• 8 Lee C T, Dunn R L, Ingold C. et al .Early stage bladder cancer surveillance does not improve survival if patients progress to clinical T2 disease. AUA 2004 abstract 310
• 9 Malmstrom P U, Busch C, Norlen B J. Recurrence, progression and survival in bladder cancer. A retrospective analysis of 232 patients with greater than or equal to 5-year follow-up.  Scand J Urol Nephrol. 1987;  21 (3) 185-195
• 10 Malmstrom P U, Wijkstrom H, Lundholm C, Wester K, Busch C, Norlen B J. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group.  J Urol. 1999;  161 1124-1127
• 11 Patard J, Moudouni S, Saint F. et al . Tumor progression and survival in patients with T1G3 bladder tumors : multicentric retrospective study comparing 94 patients treated during 17 years.  Urology. 2001;  58 (4) 551-556
• 12 Peyromaure M, Zerbib M. T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival. BJU Int 2004 93(1): 60-63
• 13 Prout Jr G R, Barton B A, Griffin P P, Friedell G H. Treated history of noninvasive grade 1 transitional cell carcinoma. The National Bladder Cancer Group.  J Urol. 1992;  148 (5) 1413-1419
• 14 Sanchez-Ortiz R F, Huang W C, Mick R, Arsdalen K N Van, Wein A J, Malkowicz S B. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma.  J Urol. 2003;  169 (1) 110-115
• 15 Stein J P, Lieskovsky G, Cote R, Groshen S, Feng A C, Boyd S, Skinner E, Bochner B, Thangathurai D, Mikhail M, Raghavan D, Skinner D G. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.  J Clin Oncol. 2001;  19 666-675
• 16 Stöckle M, Alken P, Engelmann U, Jacobi G H, Riedmiller H, Hohenfellner R. Radical cystectomy - often too late?.  Eur Urol. 1987;  13 (6) 361-36
• 17 Thalmann G N, Markwalder R, Shahin O, Burkhard F C, Hochreiter W W, Studer U E. Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy?.  J Urol. 2004;  172 (1) 70-75